Related Experiment Video
Updated: May 20, 2025
08:15
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
478
Ilex Guayusa Tea Improves Glycaemia and Autonomic Modulation in Female Streptozotocin-Induced Diabetic Rats
Tafne Coelho Mello1, Danielle da Silva Dias1,2,3, Nathalia Bernardes1,4
1Laboratory of Translational Physiology, Universidade Nove de Julho (UNINOVE), São Paulo 01504-001, Brazil.
Pharmaceuticals (Basel, Switzerland)
|March 27, 2025
Summary
Ilex guayusa tea may help manage diabetes complications by improving metabolic and autonomic function in diabetic rats. This study found it mitigated autonomic dysfunction, a poor prognostic marker in diabetes.
Area of Science:
- Cardiovascular research
- Metabolic research
- Pharmacology
Background:
- Cardiovascular diseases are a major cause of death in diabetic patients.
- Streptozotocin (STZ)-induced diabetic rats mimic human diabetic symptoms, including hyperglycemia and autonomic dysfunction.
- Ilex guayusa's potential effects on cardiovascular, metabolic, and oxidative stress parameters in diabetes require investigation.
Purpose of the Study:
- To evaluate the effects of Ilex guayusa tea on cardiovascular, autonomic, metabolic, and oxidative stress in STZ-induced diabetic rats.
- To assess the antioxidant and phytochemical properties of Ilex guayusa.
Main Methods:
- Diabetes was induced in female Wistar rats using streptozotocin (STZ).
- Diabetic rats received Ilex guayusa tea (3.0 g/L) ad libitum for 21 days.
- Cardiovascular, autonomic, metabolic, and oxidative stress parameters were measured.
Main Results:
- Diabetic rats showed increased glycemia and decreased body mass compared to controls.
- Ilex guayusa consumption improved vascular sympathetic modulation (LF-SAP, VAR-SAP) in diabetic rats.
- Reduced vascular sympathetic modulation was inversely correlated with glycemia.
Conclusions:
- Ilex guayusa tea may mitigate metabolic and autonomic dysfunction associated with diabetes.
- The findings suggest a potential therapeutic role for Ilex guayusa in managing diabetic complications.
- Further research into the antioxidant and phytochemical properties of Ilex guayusa is warranted.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
277
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
277
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
144
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
144
01:23Dipeptidyl Peptidase 4 Inhibitors
146
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
146
01:06Oral Hypoglycemic Agents: Glinides
116
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
116
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.0K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.0K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
134
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
134